Background: There is evidence that homocysteine contributes to various neurodegenerative disorders. Objective: To assess the values of homocysteine in patients with Creutzfeldt-Jakob disease (CJD) in both cerebrospinal fluid (CSF) and plasma. Methods: Study design: Case control study. Total homocysteine was quantified in CSF and plasma samples of CJD patients (n = 13) and healthy controls (n = 13). Results: Mean values in healthy controls: 0.15 Ìmol/l B 0.07 (CSF) and 9.10 Ìmol/l B 2.99 (plasma); mean values in CJD patients: 0.13 Ìmol/l B 0.03 (CSF) and 9.22 Ìmol/l B 1.81 (plasma). No significant differences between CJD patients and controls were observed (Mann-Whitney U, p 1 0.05). Conclusions: The results indicate that the CSF and plasma of CJD patients showed no higher endogenous levels of homocysteine as compared to normal healthy controls. These findings provide no evidence for an additional role of homocysteine in the pathogenetic mechanisms underlying CJD neurodegeneration.
Introduction
Elevated plasma homocysteine concentrations are linked to neuropsychiatric disorders such as alcoholism and alcohol-related brain atrophy [3] , Alzheimer's disease (AD), and cognitive impairment [8] . Furthermore, increased plasma homocysteine levels are an independent risk factor for the development of AD [8] . Homocysteine is a neurotoxic excitatory amino acid, which plays a role in a shared biochemical cascade involving overstimulation of N-methyl-D-aspartate (NMDA) receptors, oxidative stress, activation of caspases, DNA damage, and mitochondrial dysfunction. These mechanisms are believed to be important in the pathogenesis of neurotoxicity and excitotoxicity [3, 6] .
Prion diseases or spongiform encephalopathies are a group of fatal neurodegenerative disorders including Creutzfeldt-Jakob disease (CJD). Since the chemical composition of human cerebrospinal fluid (CSF) is considered to reflect brain metabolism, we investigated homocysteine levels in the CSF of CJD patients and healthy controls. Additionally, plasma samples were examined for total homocysteine levels. It was the aim of the present pilot study to assess the possible involvement of homocysteine in the pathogenesis of CJD.
Methods
The present case control study was approved by the local Ethics Committee. Diagnosis of CJD and laboratory investigations were performed as previously described [1, 7, 10] . 13 CJD patients were examined clinically by a member of the German CJD Surveillance Study Group and each patient underwent a detailed neurologic examination. The mean age of CJD patients was 65.8 years (range 53.8-83.5 years). All patients of this group have succumbed to their disease, and the diagnosis CJD was confirmed neuropathologically using immunohistochemistry for the prion protein in all cases. 14-3-3 protein was detected according to various methods [7, 10, 11] in all 13 CJD patients. The controls consisted of 13 healthy subjects with normal cognition and without a diagnosis of any psychiatric or neurologic disease. After complete description of the study to the subjects, written informed consent was obtained. Controls were matched to cases by age and gender.
Screening for non-genetic factors possibly associated with elevated homocysteine levels such as lifestyle (alcohol abuse, nutritional status, medication), endocrinological conditions and other diseases (i.e. diabetes mellitus, cardiovascular diseases), laboratory methods and measurements (vitamins B 12 , B 6 and folate) were performed on the basis of a previous study [2] . All patients and controls were classified as normally nourished (data not shown). Under these conditions, a plasma homocysteine reference interval of 4.9-11.7 Ìmol/l was defined as normal according to Ubbink et al. [9] . Normal ranges for CSF homocysteine are not known.
Total homocysteine in plasma and cerebrospinal fluid (CSF) was measured by an enzyme-linked immunosorbent assay (Axis ® Homocysteine EIA, Germany/Norway, IBL-No. AX 513 01). Statistical analysis: The significance of differences between groups was evaluated by the non-parametric Mann-Whitney U test. Results are presented as the central tendency (mean) B SD. p ! 0.05 (two-tailed) was considered to indicate statistical significance.
Results
As shown in figure 1, CSF as well as plasma homocysteine levels did not differ significantly between CJD patients (n = 13) and controls (n = 13). Central tendencies (CT or 'mean' B SD in Ìmol/l) in controls: 0.15 B 0.07 (CSF) and 9.10 B 2.99 (plasma); CT values in CJD patients: 0.13 B 0.03 (CSF) and 9.22 B 1.81 (plasma). Thus, no significant differences between CJD patients and controls in respect to homocysteine concentrations in samples of CSF (Z = -0.46, p = 0.65) and plasma (Z = -0.33, p = 0.76) were found. Furthermore, in both groups homocysteine concentrations were within the reference interval (4.9-11.7 Ìmol/l). 
Discussion
To our knowledge, this is the first study evaluating homocysteine levels in patients suffering from (sporadic) CJD. However, we did not detect any significant differences of homocysteine levels in CSF or plasma. A number of reviews detail acute or chronic pathophysiology in which free radicals and homocysteine express their toxicity in neurodegenerative disorders [5] . Taking into account that there is no evidence of oxidative stress in CJD patients [1] the results of the present study are in line with these previous observations. However, determining homocysteine levels in an earlier stage of CJD patients might deliver other results. Despite the identification of hyperhomocysteinemia as an independent risk factor for neurodegenerative disorders such as AD [8] , little is known about the presence of homocysteine in the CSF. However, similar results were found in a recent study of 18 healthy adults with CSF homocysteine concentrations between 0.015 and 0.140 Ìmol/l [4] .
Furthermore, it must be taken into account that an intracellular accumulation of homocysteine leads to hyperhomocysteinemia. Thus, the neurotoxicity of homocysteine is not only caused by an elevated extracellular homocysteine concentration, but especially by the toxic effects that can be triggered by the intracellular hyperhomocysteinemia and can affect the intracellular compartments [3] .
Since we could not disclose an intracellular accumulation of homocysteine, further studies are needed which should be directed to CJD brain tissue. However, at this moment we conclude that homocysteine possibly does not play a pathophysiological role in CJD and may not serve as a biological marker of CJD but may be useful in the differential diagnosis of other neurodegenerative disorders, in particular AD.
